All AbMole products are for research use only, cannot be used for human consumption.
NAZ2329 is the first cell-permeable inhibitor of R5 subfamily of receptor-type protein tyrosine phosphatases (RPTPs), allosterically and preferentially inhibits PTPRZ (IC50=7.5 µM for hPTPRZ1) and PTPRG (IC50=4.8 µM for hPTPRG) over other PTPs. NAZ2329 binds to the active D1 domain and more potently inhibits PTPRZ-D1 fragment (IC50 of 1.1 µM) than the whole intracellular (D1 + D2) fragment (IC50 of 7.5 µM).
NAZ2329 can effectively inhibit tumor growth of the glioblastoma cells. NAZ2329 (25 µM; 0-90 min) obviously promotes the phosphorylation level of paxillin at Tyr-118 site, leading to inhibition for PTPR substrate.
In vivo, NAZ2329 (22.5 mg/kg; intraperitoneal injection; twice per week; 40 days) has a moderate inhibitory effect.
| Molecular Weight | 501.56 |
| Formula | C21H18F3NO4S3 |
| Solubility (25°C) | DMSO 80 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related Phosphatase Products |
|---|
| 4-Methylumbelliferyl phosphate
4-Methylumbelliferyl phosphate (4-MUP), an anionic organophosphate, is a acid and alkaline phosphatase fluorogenic substrate. |
| M5N36
M5N36 is a potent and selective Cdc25C inhibitor with IC50 values of 0.15, 0.19, 0.06 µM for Cdc25A, Cdc25B, Cdc25C, respectively. |
| DPM-1003
DPM-1003 is an orally potent, specific inhibitor of PTP1B. |
| D-3
D-3, a phosphorpeptide, is an efficient, simple, and specific iPSC-eliminating agent. |
| EGF Receptor Substrate 2 (Phospho-Tyr5)
EGF Receptor Substrate 2 (Phospho-Tyr5) acetate, a biologically active peptide, is a tyrosine phosphate substrate. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
